A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

por Woodcock, Victoria K, Clive, Sally, Wilson, Richard H, Coyle, Vicky M, Stratford, Michael R L, Folkes, Lisa K, Eastell, Richard, Barton, Claire, Jones, Paul, Kazmi-Stokes, Shamim, Turner, Helen, Halford, Sarah, Harris, Adrian L, Middleton, Mark R
Publicado 2018

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

por Davies, Andrew, Cummin, Thomas E, Barrans, Sharon, Maishman, Tom, Mamot, Christoph, Novak, Urban, Caddy, Josh, Stanton, Louise, Kazmi-Stokes, Shamim, McMillan, Andrew, Fields, Paul, Pocock, Christopher, Collins, Graham P, Stephens, Richard, Cucco, Francesco, Clipson, Alexandra, Sha, Chulin, Tooze, Reuben, Care, Matthew A, Griffiths, Gareth, Du, Ming-Qing, Westhead, David R, Burton, Catherine, Johnson, Peter W M
Publicado 2019